0001181158-11-000004.txt : 20111206
0001181158-11-000004.hdr.sgml : 20111206
20111206091752
ACCESSION NUMBER: 0001181158-11-000004
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20111205
FILED AS OF DATE: 20111206
DATE AS OF CHANGE: 20111206
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MAGNUSON TERRY
CENTRAL INDEX KEY: 0001181158
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-27570
FILM NUMBER: 111244576
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PHARMACEUTICAL PRODUCT DEVELOPMENT INC
CENTRAL INDEX KEY: 0001003124
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 561640186
STATE OF INCORPORATION: NC
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 929 NORTH FRONT STREET
CITY: WILMINGTON
STATE: NC
ZIP: 28401
BUSINESS PHONE: 9102510081
MAIL ADDRESS:
STREET 1: 929 NORTH FRONT STREET
CITY: WILMINGTON
STATE: NC
ZIP: 28401
4
1
edgar.xml
PRIMARY DOCUMENT
X0304
4
2011-12-05
1
0001003124
PHARMACEUTICAL PRODUCT DEVELOPMENT INC
PPDI
0001181158
MAGNUSON TERRY
408 BAYBERRY DRIVE
CHAPEL HILL
NC
27514
1
0
1
0
Common Stock
2011-12-05
4
D
0
17633
33.25
D
0
D
Stock Options (to buy)
24.26
2011-12-05
4
D
0
9090
0
D
9090
9090
0
D
Stock Options (to buy)
28.52
2011-12-05
4
D
0
9095
0
D
Common Stock
9095
0
D
Stock Options (to buy)
24.52
2011-12-05
4
D
0
10496
0
D
Common Stock
10496
0
D
Stock Options (to buy)
19.19
2011-12-05
4
D
0
14053
0
D
Common Stock
14053
0
D
Stock Options (to buy)
41.32
2011-12-05
4
D
0
6485
0
D
Common Stock
6485
0
D
Stock Options (to buy)
32.67
2011-12-05
4
D
0
6341
0
D
Common Stock
6341
0
D
Stock Options (to buy)
12.37
2011-12-05
4
D
0
12421
0
D
Common Stock
12421
0
D
Stock Options (to buy)
13.12
2011-12-05
4
D
0
16561
0
D
Common Stock
16561
0
D
Stock Options (to buy)
15.28
2011-12-05
4
D
0
16561
0
D
Common Stock
16561
0
D
Stock Options (to buy)
22.98
2011-12-05
4
D
0
5650
0
D
Common Stock
5650
0
D
Stock Options (to buy)
34.18
2011-12-05
4
D
0
4113
0
D
Common Stock
4113
0
D
Pursuant to the Agreement and Plan of Merger (the "Agreement") by and among Pharmaceutical Prodcut Development, Inc., Jaguar Holdings, LLC and Jaguar Merger Sub, Inc. dated as of October 2, 2011, on the effective date of the merger contemplated by the Agreement (the "Merger"), each of these shares of common stock was automatically converted into the right to receive $33.25.
These stock options were cancelled pursuant to the Merger in exchange for a cash payment equal to the difference (if any) between the exercise price of the stock options and $33.25 multiplied by the number of shares subject to such stock options less any applicable withholding taxes. The options were scheduled to vest in three equal increments on 7/30/2011, 7/30/2012 and 7/30/2013 but vesting was accelerated due to the Merger.
These stock options were cancelled pursuant to the Merger in exchange for a cash payment equal to the difference (if any) between the exercise price of the stock options and $33.25 multiplied by the number of shares subject to such stock options less any applicable withholding taxes.
Lisa C. Noecker attorney-in-fact for Terry Magnuson
2011-12-06